FIELD: biotechnology.
SUBSTANCE: invention relates to versions of emicizumab with reduced activity of the blood coagulation factor VIII (FVIII) mimetic, and can be used to reduce the content of impurities in the recombinant production of emicizumab. The proposed Q-CDR truncated version of emicizumab is characterized by the removal of amino acid residue R at position 12 from the N-terminal end of the heavy chain CDR2 sequence with SEQ ID NO: 2 and cleavage of the variable region at the deletion site.
EFFECT: invention provides the obtaining of emicizumab with a low content of the specified version in CHO cells.
5 cl, 9 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY HAVING HIGH ACTIVITY, ALTERNATIVE FUNCTION OF COFACTOR FVIII | 2017 |
|
RU2821642C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| BISPECIFIC ANTIBODIES TO CCL2 | 2020 |
|
RU2819613C1 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
| COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
